These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4412241)

  • 1. Brain glutamic acid decarboxylase activity in Parkinson's disease.
    Rinne UK; Laaksonen H; Riekkinen P; Sonninen V
    Eur Neurol; 1974; 12(1):13-9. PubMed ID: 4412241
    [No Abstract]   [Full Text] [Related]  

  • 2. L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Hornykiewicz O
    Nature; 1973 Jun; 243(5409):521-3. PubMed ID: 4743649
    [No Abstract]   [Full Text] [Related]  

  • 3. Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
    Howse PM; Matthews WB
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):27-9. PubMed ID: 4570903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamic-acid decarboxylase and choline acetylase in Huntington's chorea and Parkinson's disease.
    McGeer PL; McGeer EG; Fibiger HC
    Lancet; 1973 Sep; 2(7829):622-3. PubMed ID: 4125419
    [No Abstract]   [Full Text] [Related]  

  • 5. Brain histidine decarboxylase activity in Parkinson's disease.
    Garbarg M; Javoy-Agid F; Schwartz JC; Agid Y
    Lancet; 1983 Jan; 1(8314-5):74-5. PubMed ID: 6129410
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of globus pallidus lesions and Parkinson's disease on brain glutamic acid decarboxylase.
    McGeer PL; McGeer EG; Wada JA; Jung E
    Brain Res; 1971 Sep; 32(2):425-31. PubMed ID: 4944072
    [No Abstract]   [Full Text] [Related]  

  • 7. Glutamic acid decarboxylase in Parkinson's disease and epilepsy.
    McGeer PL; McGeer EG; Wada JA
    Neurology; 1971 Oct; 21(10):1000-7. PubMed ID: 5165300
    [No Abstract]   [Full Text] [Related]  

  • 8. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
    Sharpe JA; Rewcastle NB; Lloyd KG; Hornykiewicz O; Hill M; Tasker RR
    J Neurol Sci; 1973 Jul; 19(3):275-86. PubMed ID: 4716845
    [No Abstract]   [Full Text] [Related]  

  • 9. Brain acetylcholinesterase in Parkinson's disease.
    Rinne UK; Riekkinen P; Sonninen V; Laaksonen H
    Acta Neurol Scand; 1973; 49(2):215-26. PubMed ID: 4718190
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 11. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 12. Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study.
    McGeer PL; McGeer EG; Fibiger HC
    Neurology; 1973 Sep; 23(9):912-7. PubMed ID: 4146891
    [No Abstract]   [Full Text] [Related]  

  • 13. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduced glutamic-acid-decarboxylase activity of post-mortem brain in Huntington's chorea.
    Bird ED; Mackay AV; Rayner CN; Iversen LL
    Lancet; 1973 May; 1(7812):1090-2. PubMed ID: 4122011
    [No Abstract]   [Full Text] [Related]  

  • 18. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.